# Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer

> **NCT00006118** · PHASE2 · UNKNOWN · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group**

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00006118
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006118, "Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*